Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
Down 3.8% on 2x ave vol. Any news, or just poor overall market dynamics. I am looking for news flow to pick up in August before 1st half results. FL
Everything is suffering, inflation numbers US tomorrow will probably mean the difference between red or green.
A few of the jobs are regulatory affairs personnel in the U.S. Is this a sign that BCART is realizing they need to beef up for interactions with FDA? I wish we had more insights into the MSI 510K. My biggest fear for BCART is that there product Idylla seeks to disrupt a new high growth field Oncology MDx -personalized medicine- health care automation, etc and as such the regulatory processes may be wired to protect local domestic business. We are seeing regulatory delays through much of the developed world outside of the EU. The FDA approved Promega (a competing MSI assay) much quicker than Idylla which presumably submitted a lot of head to head comparisons supporting the application (something the FDA supposedly weights heavily in the approval process). China has thrown up some regulatory roadblocks that are keeping BCART from even filing any registrations until next year. By my count that is a couple years behind the schedule we had been guided toward. While the Japan registrations for KRAS, NRAS and MSI were filed in November by Nicherei, I believe they are also way behind the initially anticipated schedule. Hopefully the process does not languish and we hear something from Japan soon. The commonality, is that each of these markets have domestic MDx businesses that are seeking to compete with Idylla. On the other hand, the approvals in the EU and the emerging markets seem to occur on fairly predictable schedules. At some point, if BCART can collect hard evidence of my suspicions they made need to start taking this up with EU trade officials. Part of the advantage that bigger companies have is that they can put legal and lobbying heft behind their efforts. FL
www.jmdjournal.org/article/S1525-1578... Encouraging article on the role of Idylla Gene Fusion in cancer treatment. Looks like they really need a couple high placed labs or Universities to publish proposed testing algorithm's for different cancers. FL
Rolland Carlson of Immunexpress provides insights to the IVD approval process via FDA's 510K process. www.meddeviceonline.com/doc/tips-for-...
Prolonged FDA approvals, does he have some insights on that too? I wouldn't put it beyond the FDA to just delay or even flatly deny entry to a good device from another continent to protect American companies.
Good Day Don't think the system would allow outright denial if appropriate studies and documentation is filed. I do think they can delay it by requesting additional information or documentation. In the meantime Promega or other competitors have additional time to launch their MSI test or stuff the supply channels with their product. Its crappy but I think it is commonly done worldwide. FL
Mikron Asia had a great 1st half 2022. I think it is a pretty good bet that it was helped by the construction of ML3 for Wondfo-Cartis. FL "The Mikron Group’s net sales rose from CHF 139.9 million in the first half of 2021 to CHF 145.9 million in the first half of 2022 (+4.3%). A major part of the significant increase in order intake will generate sales in 2023, and in subsequent years. With a 48% share of sales, Europe (including Switzerland) remained the Mikron Group’s principal sales market in the first half of 2022. Mikron increased sales in Europe by 3.4% compared with the first half of 2021, in Asia by 60.8% while the sales in the USA decreased by -13.4%."
Artikel immunexpress ; tinyurl.com/musd9h6h
Biocartis zijn newscycle is precies al beter dit jaar maar de koers volgt niet zolang dat gapend gat in hun finances niet op een acceptable manier opgelost wordt.
I anxiously await similar articles/interviews from the user community. Testimonials from a large research oriented hospital would lend a lot more creditability. Regards FL
event.on24.com/wcc/r/3872284/0E14F30B... Memorial Sloan Kettering (MSK) is running a webinar on Idylla Gene Fusion. This is the type of user community sponsorship that can carry a lot of weight. Unfortunately the RUO designation will greatly limit usage in the US. FL
finance.yahoo.com/news/nccn-colorecta... Now would be a good time for the FDA MSI approval. FL
NSCLCToday 19:08www.genomeweb.com/scan/lung-cancer-re... A few weeks ago I hypothesized that BCART and LifeArc should strike up a relationship to partner their ABC breast cancer assay with Angle in order to make it more conducive to ctDNA liquid biopsy. The same may be true of patnering EGFR and Gene fusion assays for NSCLC. The article suggests that circulating tumor content may provide an effective means for monitoring disease progression. I can see a possible role for Angle's parasortix in mutation monitoring. I think the same results found for checkpoint inhibutors will be found for other mutation drivers. Thus, ctDNA may well become the prefered method for patient disease monitoring. It is a lot easier to draw a blood sample than to obtain a lung swab or fine needle lung sample. I think the cost of repeated NGS analyses would be prohibitive for most insurers/payers. A combination of Parasortix and PCR sequencing for EGFR, ROS, Alk etc should be much quicker and cost effective. Parasortix may well address some of the sensitivity issues associated with using Idylla for ctDNA analyses. Is anyone still out there? FL
Yes, focus op 1 September.
I'm still here. I'm actually still buying. Feeling adventurous
OzDx schreef op 16 augustus 2022 03:06 :
I'm still here. I'm actually still buying. Feeling adventurous
You have too much money.
Performance of Idylla KRAS assay on extracted DNA and de-stained cytology smears: Can we rescue small sample? Abstract Objective: KRAS is a frequently mutated gene in cancers, and with recent FDA-approved targeted therapy for the G12C mutation, testing for KRAS variants is essential. We evaluated the performance of the Idylla KRAS assay on extracted DNA and cytology smears in order to expand the utility of the assay. Methods: In total, fifty-seven human samples were analyzed. Idylla results from sixteen DNA extracted from formalin-fixed, paraffin-embedded tissues (FFPE DNA) and thirty cytology smears were compared to the reference method. We evaluated the performance of the Idylla assay using corresponding cytology smears to rescue cellblocks or surgical blocks that were quantity not sufficient (QNS) for next generation sequencing (NGS). Result: In the FFPE DNA cohort, 10 ng DNA input yielded valid results in all 16 samples, with 15 of 16 (93 %) concordant with NGS findings. In the cytology smear cohort, the Idylla KRAS assay demonstrated 100 % concordance with previous NGS results in 30 cases. In the QNS cohort, the assay was valid in all cases and KRAS mutations were identified in 3 of 11 cytology smears, including one G12C mutation. Conclusion: The Idylla KRAS assay is a high-performing, feasible, and convenient option for testing extracted DNA and cytology smears. It rescues QNS samples allowing it to be integrated into the molecular workflow as an initial screening test with remarkably quick turnaround times.
Hey Oz, What is the date on that article? I read something very similar about 2 years ago, although I recall it being focused on EGFR. Do you have any thoughts on the possible use of Angle Parasortix to harvest circulating tumor for liquid biopsy analyses on Idylla, It seems like it addresses the primary problem that Idylla is not sufficiently sensitive to low circulating tumor levels. If it has utility, perhaps we will hear that BCART and LifeArc are evaluating it for the ABC assay, Parasortix is already approved by FDA for breast cancer. FL
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee